Kiora Pharmaceuticals Inc stock is traded at $1.44, with a volume of 54,292. It is down -4.00% in the last 24 hours and down -42.40% over the past month. Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Previous Close:
$1.50
Open:
$1.49
24h Volume:
54,292
Relative Volume:
0.50
Market Cap:
$6.37M
Revenue:
$20,000
Net Income/Loss:
-$11.06M
P/E Ratio:
-
EPS:
-$2.84
Net Cash Flow:
-$10.53M
1W Performance:
-7.69%
1M Performance:
-42.40%
6M Performance:
-42.63%
1Y Performance:
-37.93%
1-Day Range:
$1.40$1.51
1-Week Range:
$1.40$1.85
52-Week Range:
$1.40$2.91
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
858-224-9600Address
169 SAXONY RD., ENCINITAS, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS